Navigation Links
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Date:5/13/2009

- Available this week, Cimzia(R) (certolizumab pegol), the only pegylated anti-TNF, offers a new treatment option for U.S. adult patients suffering from moderately to severely active rheumatoid arthritis

- Patients treated with Cimzia(R), together with methotrexate, experienced rapid and significant improvements in signs and symptoms, physical function and pain as early as week one, and sustained at week 24 and for up to one year

- Patients treated with Cimzia(R) as a monotherapy experienced significant improvements in signs and symptoms, physical function and pain

- Cimzia(R) is available in an exclusively designed, patient-friendly, prefilled syringe resulting from the UCB partnership with OXO(R). The new syringe carries the Arthritis Foundation(TM) Ease-of-Use Commendation

- Cimzia(R) offers U.S. adult patients flexible maintenance dosing, either at two or four weeks after initial doses, and can be used together with methotrexate or as a monotherapy

ATLANTA, May 13 /PRNewswire/ -- regulated information -- UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia(R), the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia(R) can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four weeks can be considered.

In clinical trials with Cimzia(R), together with methotrexate (MTX), patients experienced a significant reduction in the signs and symptoms of RA at week 24 with some showing clinical responses within one to two weeks, compared with MTX alone. Additionally, radiographic data showed Cimzia(R), together with MTX, inhibited progression of joint damage, with a significantly smaller change from baseline in modified Total Sharp Score (TSS) at 2
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohns Patients
2. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
3. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
4. MedClean Technologies, Inc. Approved in New Jersey
5. GADA Points to Safety of FDA Approved Generics in Wake of Wellington Polo Horse Deaths from Compounded Drugs
6. DRAXIMAGE(R)s generic Sestamibi Approved for launch in USA
7. New Botox(R) Alternative Dysport(TM) FDA Approved, Ready to Rumble
8. Introducing Ashley Koff Approved (AKA): the Stamp of Nutrition for Optimal Health
9. Wyeths CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
10. Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
11. Hospital Approved Residential Water Features Kill Harmful Airborne Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Hundreds of Byetta lawsuits ( http://www.byettalawsuit.com ... forward in U.S. courts, Bernstein Liebhard LLP reports. According ... 31, 2014, Byetta and Bydureon (an extended-release version of ... that allege the drugs caused pancreatitis, pancreatic cancer and ... claims are pending in a multidistrict litigation underway in ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Lab Oven including its ... explores global and China’s top manufacturers of Lab ... and market share etc. , The report further ...
(Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
(Date:8/30/2014)... 2014 In today’s world, a good ... to get. Snoring and sleep apnea (a medical problem ... robs people and their bed partners of the rest ... 45% of the population snores and 20 million people ... these, only 10% have been diagnosed and treated; and ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... at the Kimmel Cancer Center at Thomas Jefferson ... how common blood pressure medications might help prevent ... in the laboratory that one type of pressure-lowering ... cancer cell growth and causes cell death. , ...
... Researchers at St. Jude Childrens Research Hospital have discovered ... to initiate most cases of an aggressive and often-fatal ... known as "cooperating oncogenic lesions," include the deletion of ... the development of a blood stem cell into a ...
... Now Available in ... Commercial Fitness Equipment, LAKE SUCCESS, ... monitoring and fitness assessment technology, announced today,that its patented OwnCode(R) ... can now be seamlessly and cost-effectively,incorporated into commercial fitness equipment, ...
... WESTLAKE VILLAGE, Calif., April 14 ... has been recognized for,call center operation ... Power,and Associates Certified Call Center Program(SM). ... the HealthFusion call center,operations to provide ...
... Prix Galien USA 2008 Announced for September 24, ... Nobel Laureate Walter,Gilbert, Ph.D., the Carl M. ... of Biogen, has joined fellow Nobel Laureates on ... in,biopharmaceutical research. Prix Galien USA 2008,( http://www.prix-galien-usa.com ) ...
... April 14 It,s 2 a.m. on a Sunday morning, your,dog ... weekend. What do,you do?, Well, this scenario happened to pet ... Internet about what to do for his lab mix,he realized he ... He,needed to develop a comprehensive resource for pet owners everywhere to,assist ...
Cached Medicine News:Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 3Health News:Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 2Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 3Health News:Comprehensive Pet Care Web Site Takes New Approach in Helping Pet Owners With Their Furry Members of the Family 2
(Date:8/29/2014)... 2014  Pacific Medical Data Solutions is excited to ... . The main website, along with the site,s blog, ... services and content relevant to the medical billing industry. ... viewers can now better understand how PMDS products help ... create a more visible platform about medical billing best ...
(Date:8/29/2014)... , August 29, 2014 ... and collaboration software has announced a major new deal ... founded by renowned pathology expert, Dr. Marius Nap ... of the 26th European Congress of Pathology which is ... the ExCeL Arena, London where ...
(Date:8/29/2014)... AMSTERDAM , August 29, 2014 ... invited to participate in the inaugural Tweetchat taking ... CPhI Worldwide , organised by UBM ... October 2014. #CPhIChat is a first of its ... media working across the supply chain, aimed to ...
Breaking Medicine Technology:PMDS Announces New Website 2Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3
... 21, 2011 Express Scripts, Inc. (NASDAQ: ESRX ... ) today announced that they have entered into a definitive ... per share in cash and stock, or $29.1 billion, based ... cash and 0.81 shares for each Medco share they own ...
... AstraZeneca (NYSE: AZN ) announced today ... approved BRILINTA™ (ticagrelor) tablets to reduce the rate of ... in adult patients with acute coronary syndrome (ACS), compared ... assets associated with this release, please click: http://multivu.prnewswire.com/mnr/astrazeneca/50355/ ...
Cached Medicine Technology:Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 2Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 3Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 4Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 5Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 6Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 7Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 8Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 9Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 10Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 11Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 12Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 13Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion 14FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US 2FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US 3FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US 4FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US 5FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US 6FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US 7
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: